1
|
Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixao CS, Carvalho MS, Jesus-Nunes AP, Vieira F, Magnavita G, Bandeira ID, Mello RP, Beanes G, Silva SS, Echegaray M, Carvalho LP, Machado P, Sampaio AS, Cardoso TDA, Kapczinski F, Lacerda ALT, Quarantini LC. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends Psychiatry Psychother 2023; 45:e20210298. [PMID: 34904800 PMCID: PMC9991420 DOI: 10.47626/2237-6089-2021-0298] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 09/24/2021] [Indexed: 11/20/2022]
Abstract
OBJECTIVES Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). METHODS Participants (n = 53) are from a randomized, double-blind clinical trial comparing the efficacy of single-dose ketamine (0.5mg/kg, n = 27) and esketamine (0.25mg/kg, n = 26) in TRD. Depression severity was assessed before and 24 hours, 72 hours, and 7 days after the intervention, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Blood samples were collected before infusion, 24 hours, and 7 days afterwards. RESULTS There were no significant changes in BDNF levels at post-infusion evaluation points, and no difference in BDNF levels comparing ketamine and esketamine. Both drugs exhibited similar therapeutic effect. There was no association between BDNF levels and response to treatment or severity of depressive symptoms. CONCLUSION There was no significant treatment impact on BDNF serum levels - neither with ketamine nor esketamine - despite therapeutic response. These results suggest that ketamine or esketamine intervention for TRD has no impact on BDNF levels measured at 24 hours and 7 days after the infusion.
Collapse
Affiliation(s)
- Ana Teresa Caliman-Fontes
- Faculdade de Medicina da BahiaUFBASalvadorBABrazil Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil.
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Gustavo C. Leal
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Serviço de PsiquiatriaHospital Universitário Professor Edgard SantosUFBASalvadorBABrazil Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Fernanda S. Correia-Melo
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Camilla S. Paixao
- Laboratório de Pesquisas ClínicasInstituto Gonçalo MonizFiocruzSalvadorBABrazil Laboratório de Pesquisas Clínicas, Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil.
- Serviço de ImunologiaUFBASalvadorBABrazil Serviço de Imunologia, UFBA, Salvador, BA, Brazil.
| | - Michelle S. Carvalho
- Laboratório Interdisciplinar de Neurociências ClínicasUniversidade Federal de São PauloSão PauloBrazil Laboratório Interdisciplinar de Neurociências Clínicas, Universidade Federal de São Paulo, São Paulo, Brazil.
| | - Ana Paula Jesus-Nunes
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Flavia Vieira
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Guilherme Magnavita
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Igor D. Bandeira
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Rodrigo P. Mello
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Graziele Beanes
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Samantha S. Silva
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Serviço de PsiquiatriaHospital Universitário Professor Edgard SantosUFBASalvadorBABrazil Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, UFBA, Salvador, BA, Brazil.
| | - Mariana Echegaray
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Lucas P. Carvalho
- Laboratório de Pesquisas ClínicasInstituto Gonçalo MonizFiocruzSalvadorBABrazil Laboratório de Pesquisas Clínicas, Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil.
- Serviço de ImunologiaUFBASalvadorBABrazil Serviço de Imunologia, UFBA, Salvador, BA, Brazil.
| | - Paulo Machado
- Laboratório de Pesquisas ClínicasInstituto Gonçalo MonizFiocruzSalvadorBABrazil Laboratório de Pesquisas Clínicas, Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil.
- Serviço de ImunologiaUFBASalvadorBABrazil Serviço de Imunologia, UFBA, Salvador, BA, Brazil.
| | - Aline S. Sampaio
- Faculdade de Medicina da BahiaUFBASalvadorBABrazil Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil.
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| | - Taiane de A. Cardoso
- Department of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonONCanada Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
| | - Flávio Kapczinski
- Mood Disorders ProgramDepartment of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonONCanada Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
| | - Acioly L. T. Lacerda
- Laboratório Interdisciplinar de Neurociências ClínicasUniversidade Federal de São PauloSão PauloBrazil Laboratório Interdisciplinar de Neurociências Clínicas, Universidade Federal de São Paulo, São Paulo, Brazil.
| | - Lucas C. Quarantini
- Faculdade de Medicina da BahiaUFBASalvadorBABrazil Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil.
- Departamento de Neurociências e Saúde MentalFaculdade de Medicina da BahiaUFBASalvadorBABrazil Laboratório de Neuropsicofarmacologia, Departamento de Neurociências e Saúde Mental, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
- Serviço de PsiquiatriaHospital Universitário Professor Edgard SantosUFBASalvadorBABrazil Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, UFBA, Salvador, BA, Brazil.
- Programa de Pós-Graduação em Medicina e SaúdeFaculdade de Medicina da BahiaUFBASalvadorBABrazil Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.
| |
Collapse
|
2
|
Lira SB, Vieira F, Cavalcanti DE, Souza-Marques B, Netto LR, Correia-Melo FS, Leal GC, Pereira JL, Santos LL, Guedes GM, Teles CA, Cardoso TDA, Miranda-Scippa Â, Kapczinski F, Lacerda ALT, Koenen KC, Turecki G, Quarantini LC. Suicide attempt, impulsivity, and exposure to trauma in college students. Braz J Psychiatry 2022; 44:279-288. [PMID: 35262616 PMCID: PMC9169478 DOI: 10.1590/1516-4446-2021-2175] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 11/02/2021] [Indexed: 11/21/2022]
Abstract
OBJECTIVES Past suicide attempt (SA) is one of the most important risk factors for suicide death. An ideation-to-action framework posits that impulsivity, potentially traumatic events, and mental disorders also play a role in increasing suicide risk. This study aimed to assess the association between trait impulsivity, lifetime exposure to trauma, and post-traumatic stress disorder (PTSD) with SA in a sample of Brazilian college students. METHODS A total of 2,137 participants filled self-reported questionnaires consisting of a sociodemographic and clinical questionnaire, Trauma History Questionnaire, Post-Traumatic Stress Disorder Checklist - Civilian version, and Barratt Impulsiveness Scale. RESULTS Our findings suggest that trait impulsivity may be interpreted as exerting a distal effect on SA, even in the presence of other variables - such as trauma history, psychological neglect, and PTSD - which also increase the odds of SA. High and medium levels of impulsivity, history of trauma, and PTSD increased the likelihood of SA. CONCLUSIONS Intervention strategies to prevent SA may target trait impulsivity and exposure to traumatic experiences.
Collapse
Affiliation(s)
- Sidnei B Lira
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Flávia Vieira
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil.,Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Diogo E Cavalcanti
- Centro Universitário Social da Bahia, Salvador, BA, Brazil.,Centro Universitário Jorge Amado, Salvador, BA, Brazil
| | - Breno Souza-Marques
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil.,Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Liana R Netto
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Fernanda S Correia-Melo
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil.,Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Gustavo C Leal
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil.,Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Juliana L Pereira
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Lene L Santos
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Gisela M Guedes
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Carlos A Teles
- Centro de Pesquisa Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil
| | - Taiane de A Cardoso
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Ângela Miranda-Scippa
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil
| | - Flavio Kapczinski
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Acioly L T Lacerda
- Laboratório Interdisciplinar de Neurociências Clínicas, Universidade Federal de São Paulo, São Paulo, SP, Brazil
| | - Karestan C Koenen
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Gustavo Turecki
- McGill Group for Suicide Studies, Douglas Mental Health University Institute & Department of Psychiatry, McGill University, Montreal, Canada
| | - Lucas C Quarantini
- Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, BA, Brazil.,Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brazil
| |
Collapse
|
3
|
Ballester PL, Cardoso TDA, Moreira FP, da Silva RA, Mondin TC, Araujo RM, Kapczinski F, Frey BN, Jansen K, de Mattos Souza LD. 5-year incidence of suicide-risk in youth: A gradient tree boosting and SHAP study. J Affect Disord 2021; 295:1049-1056. [PMID: 34706413 DOI: 10.1016/j.jad.2021.08.033] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 07/15/2021] [Accepted: 08/21/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Machine learning methods for suicidal behavior so far have failed to be implemented as a prediction tool. In order to use the capabilities of machine learning to model complex phenomenon, we assessed the predictors of suicide risk using state-of-the-art model explanation methods. METHODS Prospective cohort study including a community sample of 1,560 young adults aged between 18 and 24. The first wave took place between 2007 and 2009, and the second wave took place between 2012 and 2014. Sociodemographic and clinical characteristics were assessed at baseline. Incidence of suicide risk at five-years of follow-up was the main outcome. The outcome was assessed using the Mini Neuropsychiatric Interview (MINI) at both waves. RESULTS The risk factors for the incidence of suicide risk at follow-up were: female sex, lower socioeconomic status, older age, not studying, presence of common mental disorder symptoms, and poor quality of life. The interaction between overall health and socioeconomic status in relation to suicide risk was also captured and shows a shift from protection to risk by socioeconomic status as overall health increases. LIMITATIONS Proximal factors associated with the incidence of suicide risk were not assessed. CONCLUSIONS Our findings indicate that factors related to poor quality of life, not studying, and common mental disorder symptoms of young adults are already in place prior to suicide risk. Most factors present critical non-linear patterns that were identified. These findings are clinically relevant because they can help clinicians to early detect suicide risk.
Collapse
Affiliation(s)
- Pedro L Ballester
- Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
| | - Taiane de A Cardoso
- Department of Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil; Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Fernanda Pedrotti Moreira
- Department of Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil
| | - Ricardo A da Silva
- Department of Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil
| | - Thaíse Campos Mondin
- Department of Student Affairs, Federal University of Pelotas, Pelotas, RS, Brazil
| | - Ricardo M Araujo
- Center for Technological Development, Federal University of Pelotas, Pelotas, RS, Brazil
| | - Flavio Kapczinski
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil; Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; Bipolar Disorder Program, Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Porto Alegre, RS, Brazil; Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Benicio N Frey
- Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
| | - Karen Jansen
- Department of Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil
| | - Luciano D de Mattos Souza
- Department of Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil; Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS, Brazil.
| |
Collapse
|
4
|
Peters RB, Xavier J, Mondin TC, Cardoso TDA, Ferreira FB, Teixeira L, Gräeff K, Quevedo LDA, Jansen K, Souza LD, Oses JP, Pinheiro RT, da Silva RA, Ghisleni G. BDNF Val66Met polymorphism and resilience in major depressive disorder: the impact of cognitive psychotherapy. Braz J Psychiatry 2020; 43:22-28. [PMID: 32844885 PMCID: PMC7861181 DOI: 10.1590/1516-4446-2019-0726] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 02/21/2020] [Indexed: 11/22/2022]
Abstract
Objective: Clinical and biological correlates of resilience in major depressive disorder are scarce. We aimed to investigate the effect of the Val66Met polymorphism in the BDNF gene on resilience scores in major depressive disorder patients and evaluate the polymorphism’s moderation effect on resilience scores in response to cognitive therapy. Method: A total of 106 major depressive disorder patients were enrolled in this clinical randomized study. The Resilience Scale and the Hamilton Rating Scale for Depression were applied at baseline, post-treatment, and at six months of follow-up. Blood samples were obtained at baseline for molecular analysis. Results: The baseline resilience scores were higher in patients with the Met allele (114.6±17.6) than in those with the Val/Val genotype (104.04±21.05; p = 0.037). Cognitive therapy treatment increased resilience scores (p ≤ 0.001) and decreased depressive symptoms (p ≤ 0.001). In the mixed-effect model, the Val/Val genotype represented a decrease in resilience scores (t218 = -1.98; p = 0.048), and the Val66Met polymorphism interacted with sex to predict an increase in total resilience scores during cognitive treatment (t218 = 2.69; p = 0.008). Conclusion: Our results indicate that cognitive therapy intervention could improve resilience in follow-up, considering that gender and genetic susceptibility are predicted by the Val66Met polymorphism.
Collapse
Affiliation(s)
- Renata B Peters
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Janaína Xavier
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Thaíse C Mondin
- Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil
| | - Taiane de A Cardoso
- Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
| | - Fabiana B Ferreira
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Liana Teixeira
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Kiane Gräeff
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Luciana de A Quevedo
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Karen Jansen
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Luciano D Souza
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Jean P Oses
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Ricardo T Pinheiro
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Ricardo A da Silva
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Gabriele Ghisleni
- Programa de Pós-Graduação em Saúde e Comportamento (PPGSC), Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| |
Collapse
|
5
|
Vieira IS, Pedrotti Moreira F, Mondin TC, Cardoso TDA, Jansen K, Souza LDDM, da Silva RA. Childhood trauma and bipolar spectrum: a population-based sample of young adults. Trends Psychiatry Psychother 2020; 42:115-121. [DOI: 10.1590/2237-6089-2019-0046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 11/12/2019] [Indexed: 11/21/2022]
|
6
|
Moreira FP, Jansen K, Cardoso TDA, Mondin TC, Magalhães PV, Kapczinski F, Souza LDM, da Silva RA, Oses JP, Wiener CD. Metabolic syndrome and psychiatric disorders: a population-based study. ACTA ACUST UNITED AC 2018; 41:38-43. [PMID: 30328961 PMCID: PMC6781708 DOI: 10.1590/1516-4446-2017-2328] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Accepted: 04/01/2018] [Indexed: 12/25/2022]
Abstract
Objective: To identify the association of metabolic syndrome (MetS) and psychiatric disorders in young adults in southern Brazil. Methods: This population based cross-sectional study involved a total of 1,023 young adults between the ages of 21 and 32 years. Current episodes of psychiatric disorders were assessed using the Mini International Neuropsychiatric Interview – Plus version. MetS was evaluated using the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III). Results: Of the 1,023 participants, 24.3% were identified with MetS, 13.5% were diagnosed with anxiety disorders, 7.5% with current depression, 3.9% with bipolar disorders and 10.1% were at risk of suicide. MetS was associated with ethnicity (p = 0.022), excess weight (p < 0.001), current anxiety disorders (p < 0.001), current mood disorders (bipolar disorder in mood episode and current depression) (p < 0.001), and suicide risk (p < 0.001). Conclusions: MetS was associated with psychiatric disorders. Awareness of factors associated with MetS can help identify high-risk individuals and stimulate disease prevention and control programs, as well as lifestyle changes.
Collapse
Affiliation(s)
- Fernanda Pedrotti Moreira
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Karen Jansen
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Taiane de A Cardoso
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Thaíse C Mondin
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Pedro V Magalhães
- Psiquiatria Molecular, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil
| | - Flavio Kapczinski
- Psiquiatria Molecular, Programa de Pós-Graduação em Psiquiatria e Ciências do Comportamento, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.,McMaster University, Hamilton, ON, Canada
| | - Luciano D M Souza
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Ricardo A da Silva
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Jean Pierre Oses
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil
| | - Carolina D Wiener
- Ciência Translacional em Transtornos Cerebrais, Departamento de Saúde e Comportamento, Universidade Católica de Pelotas (UCPel), Pelotas, RS, Brazil.,Anhanguera Educacional do Rio Grande, Rio Grande, RS, Brazil
| |
Collapse
|
7
|
Cardoso TDA, Bauer IE, Jansen K, Suchting R, Zunta-Soares G, Quevedo J, Glahn DC, Soares JC. Effect of alcohol and illicit substance use on verbal memory among individuals with bipolar disorder. Psychiatry Res 2016; 243:225-231. [PMID: 27423121 PMCID: PMC5033059 DOI: 10.1016/j.psychres.2016.06.044] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 06/16/2016] [Accepted: 06/26/2016] [Indexed: 01/13/2023]
Abstract
BACKGROUND Cognitive impairment is a well-established feature of bipolar disorder (BD). Comorbid BD and substance use leads to poor psychosocial and clinical outcomes. However, knowledge on the neurocognitive functioning of individuals with dual diagnosis is limited. The aim of this study is to assess the cognitive performance of subjects with BD, BD with comorbid alcohol use disorder (AUD), and BD with comorbid illicit substance use disorders (SUD) as compared to healthy individuals. METHODS We included 270 inpatients and outpatients with BD and 211 healthy controls. The diagnostic of BD and substance use disorder was assessed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders Axis I. Demographic and clinical information were also collected. The cognitive assessment included the Wechsler Test of Adult Reading (WTAR), and a revised version of the California Verbal Learning Test (CVLT) as part of the South Texas Assessment of Neurocognition (STAN). RESULTS The STAN was administered to 134 BD patients (100 female, M±SD: 37.37±12.74 years), 72 BD patients with AUD (40 female, M±SD: 38.42±11.82), 64 BD patients with SUD (39 female, M±SD: 34.50±10.57), and 211 healthy controls with no lifetime history of mental illness and substance use (127 female, M±SD: 34.80±12.57 years). In terms of clinical characteristics, BD+SUD showed a marginally earlier onset of illness compared to BD. Compared to HC, BD performed poorly in the immediate recall and short-delay free tests of the CVLT, while BD patients with AUD and SUD showed significant memory deficits in both the immediate recall and recognition components of the CVLT. There were no differences in memory performance between BD and BD with either AUD or SUD. CONCLUSIONS A history of substance use disorders is associated with an earlier onset of BD. BD has marked effects on processes underlying the encoding of new information, while comorbid substance use in BD impairs more specifically the recognition of previously presented information. Future longitudinal studies should evaluate the effects of AUD and SUD on illness progression and therapeutic outcomes.
Collapse
Affiliation(s)
- Taiane de A. Cardoso
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
- Translational Science on Brain Disorders, Department of Health and Behavior, Catholic University of Pelotas (UCPEL), Pelotas, RS, Brazil
| | - Isabelle E. Bauer
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
- Corresponding author. University of Texas Health Science Center at Houston. Department of Psychiatry and Behavioral Science. 1941 East Road. 77054 Houston, TX, USA. Tel.: +713 486 2624.
| | - Karen Jansen
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
- Translational Science on Brain Disorders, Department of Health and Behavior, Catholic University of Pelotas (UCPEL), Pelotas, RS, Brazil
| | - Robert Suchting
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
| | - Giovana Zunta-Soares
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
| | - João Quevedo
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
- Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
- Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA
- Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil
| | - David C. Glahn
- The Olin Neuropsychiatry Research Center, Institute of Living, and Department of Psychiatry, Yale University School of Medicine, CT, United States
| | - Jair C. Soares
- Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, United States
- Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA
| |
Collapse
|
8
|
Passos IC, Jansen K, Cardoso TDA, Colpo GD, Zeni CP, Quevedo J, Kauer-Sant'Anna M, Zunta-Soares G, Soares JC, Kapczinski F. Clinical outcomes associated with comorbid posttraumatic stress disorder among patients with bipolar disorder. J Clin Psychiatry 2016; 77:e555-60. [PMID: 27135375 DOI: 10.4088/jcp.15m09935] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Accepted: 06/22/2015] [Indexed: 10/22/2022]
Abstract
OBJECTIVE To assess clinical outcomes associated with the presence of a lifetime history of comorbid posttraumatic stress disorder in subjects with bipolar disorder. METHODS This cross-sectional study of 284 subjects with bipolar disorder (DSM-IV) assessed the association between lifetime comorbid posttraumatic stress disorder (DSM-IV) and clinical characteristics. Participants were included from January 2006 to June 2009. We assessed age at onset, number of mood episodes, presence of rapid cycling, first drug use, suicide attempts, hospitalizations, functional impairment, and quality of life. Diagnostic, clinical, and functional assessments were carried out using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient edition (SCID-I/P), the Functioning Assessment Short Test, and the World Health Organization Quality of Life scale. The number of manic episodes as assessed by SCID-I/P was the primary outcome. RESULTS The prevalence of lifetime comorbid posttraumatic stress disorder was 19.7% (56 subjects). Subjects with bipolar disorder and posttraumatic stress disorder had an accelerated course of illness, with a lower age at onset of manic/hypomanic episodes (P = .009) and earlier initiation of illicit drug use (P = .008). In addition, they were more likely to be younger when they received the diagnosis of bipolar disorder (P = .036) and had a higher number of manic/hypomanic episodes (P = .01). Quality of life was worse in all domains among subjects who presented the comorbidity, and rates of functional impairment were higher. CONCLUSIONS Comorbid posttraumatic stress disorder was associated with increased morbidity and accelerated illness progression among subjects with bipolar disorder.
Collapse
Affiliation(s)
- Ives C Passos
- Center of Excellence on Mood Disorder, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston.,Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|